Skip to main content
Fig. 2 | Respiratory Research

Fig. 2

From: Roflumilast reverses CFTR-mediated ion transport dysfunction in cigarette smoke-exposed mice

Fig. 2

Effect of oral roflumilast co-administration in cigarette smoke-exposed mice. Non-CF A/J mice were treated with roflumilast (5 mg/kg/d) once daily via oral gavage over a five-week exposure period of cigarette smoke or air delivered through a nose-only exposure system. a, b Representative tracings of nasal potential difference (NPD) measurements of air control mice treated with vehicle or roflumilast (a) and cigarette smoke exposed mice treated with vehicle or roflumilast (b). c Mean forskolin-stimulated change in NPD upon sequential perfusion of Ringer’s solution, Ringer’s solution with amiloride (100 μM), chloride-free Ringer’s alone, and chloride-free Ringer’s with forskolin (20 μM). d Mean change in NPD upon perfusion of CFTRInh-172 (10 μM). N = 5–13 mice/condition. *P < 0.05. ****P < 0.0001. Roflu = roflumilast, Veh = vehicle, CS = cigarette smoke exposed

Back to article page